← Back to Search

JAK2 Inhibitor

LY2784544 for Blood Cancer

Phase 2

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months prior to study drug (historic) until pd or participant stops study (estimated up to 24 months)

Awards & highlights

Study Summary

This trial is testing a new drug for people with myeloproliferative neoplasms, which are diseases that cause too many blood cells to be produced.

Who is the study for?

Adults with blood cancers like polycythemia vera, essential thrombocythemia, or myelofibrosis who haven't responded to or can't tolerate standard treatments (including ruxolitinib) may join. They should have a specific JAK2 mutation (except certain cohorts), be able to swallow pills, not be pregnant or breastfeeding, and agree to use contraception.Check my eligibility

What is being tested?

The trial is testing LY2784544 at 120 mg for those with myeloproliferative neoplasms who've had inadequate results from other therapies. It aims to see how well participants respond in terms of disease symptoms and progression.See study design

What are the potential side effects?

While the side effects of LY2784544 are not detailed here, similar medications often cause issues like nausea, diarrhea, liver problems, low blood counts leading to increased infection risk or bleeding tendencies. Side effects vary by individual.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months prior to study drug (historic) until pd or participant stops study (estimated up to 24 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months prior to study drug (historic) until pd or participant stops study (estimated up to 24 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months prior to study drug (historic) until pd or participant stops study (estimated up to 24 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of Participants with an Objective Response (Objective Response Rate)

Secondary outcome measures

Change in 6-item Physician Symptom Assessment

Change in Activities of Daily Living (ADL)/ Instrumental Activities of Daily Living (IADL)

Change in Bone Marrow Fibrosis Grade

+16 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: 120 mg LY2784544Experimental Treatment1 Intervention

120 milligram (mg) administered orally once daily for 6 cycles (168 days)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,613 Previous Clinical Trials

3,200,819 Total Patients Enrolled

Study DirectorEli Lilly and Company

Media Library

LY2784544 (JAK2 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01594723 — Phase 2

Blood Cancers Research Study Groups: 120 mg LY2784544

Blood Cancers Clinical Trial 2023: LY2784544 Highlights & Side Effects. Trial Name: NCT01594723 — Phase 2

LY2784544 (JAK2 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01594723 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please share any other research done on 120 mg LY2784544?

"Currently, 1 active study is underway to learn more about the effects of 120 mg LY2784544. This research project is still in Phase 3 with 0 completed trials. Most of the clinical trials for 120 mg LY2784544 are being conducted out of Wodonga, Victoria; however, there are a total of 39 locations running these sorts of tests."

Answered by AI

What other research exists in this area?

"120 mg LY2784544 has been under investigation since 2012. The first trial was sponsored by Eli Lilly and Company in 2012 and involved 110 subjects. Following the study, 120 mg LY2784544 completed Phase 2 drug approval in 2012. As of now, only one active trial is being conducted by Eli Lilly and Company."

Answered by AI

Are there any lenalidomide clinical trials taking place in Canada right now?

"This clinical trial is enrolling patients at various locations including Cleveland Clinic Foundation in Cleveland, Ohio, Weill Cornell Medical College in New york, New York, Norwalk Hospital in Norwalk, Connecticut and 24 other hospitals."

Answered by AI

Does 120 mg LY2784544 carry a high risk for dangerous side effects?

"LY2784544 120 mg received a score of 2, meaning that while there is no evidence demonstrating its efficacy, there are data supporting its safety."

Answered by AI

Are investigators currently looking for individuals to participate in this research project?

"Unfortunately, this clinical trial is not presently recruiting patients. The last update to the study was on July 21st, 2022. However, there are 2674 other trials for myeloproliferative disorders and 1 trial for 120 mg LY2784544 that are actively recruiting participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

2012. "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01594723.

All > Appendix Cancer